NXTC
NextCure, Inc.
There isn't enough reported data to score NXTC yet.
NXTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NXTC's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NXTC PE Valuation
NXTC has no meaningful PE right now: it lost money over the past year.
NXTC Forward outlook
There aren't enough analyst estimates for NXTC to show an outlook.
NXTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$10.71 | +$13.52 |
| Q2 2026 | -$12.64 | +$13.29 |
| Q1 2026 | -$21.13 | +$0.11 |
| Q4 2025 | -$23.94 | -$0.06 |
| Q3 2025 | -$24.23 | +$0.85 |
| Q2 2025 | -$25.93 | +$0.35 |
| Q1 2025 | -$21.24 | +$6.12 |
| Q4 2024 | -$23.88 | +$3.12 |
NXTC is still losing money, but far less than before: $10.71 per share over the past year, against $32.28 at its worst in late 2022.
NXTC Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2020 | 37% | N/A |
| Q4 2019 | -599% | N/A |
NXTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$6.9M | +$3.7M |
| Q3 2024 | -$11.6M | +$1.4M |
| Q2 2024 | -$10.1M | +$5M |
| Q1 2024 | -$12.6M | +$2.4M |
| Q4 2023 | -$10.7M | -$869K |
| Q3 2023 | -$13.1M | +$2.5M |
| Q2 2023 | -$15M | -$124K |
| Q1 2023 | -$15M | +$725K |
NXTC has burned cash in almost every quarter: −$42M over the past year, against −$45M the year before.
NXTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +30 shares |
| 1 year | +124% | +2.9M shares |
| 3 years | +129% | +3M shares |
| 5 years | +131% | +3M shares |
| Available history | +117% | +2.9M shares |
NXTC has 5M diluted shares, up 124% from a year ago.
NXTC Net Leverage
NXTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NXTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 39.7 | Neutral |
NXTC's weekly RSI is 50 (neutral) and its Stochastic is 40 (neutral).
NXTC PE vs Healthcare Sector
NXTC has no meaningful PE right now: it lost money over the past year.
NXTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.80 | 7.4% above |
| 20 week MA | $5.60 | 11% above |
| 50 week MA | $8.25 | 24% below |
| 100 week MA | $7.77 | 20% below |
| 200 week MA | $12.9 | 52% below |
NXTC has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 52% below its 200-week average.
NXTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $704.5 | $128.9 | -82% |
| 2021 | $128.9 | $74.2 | -42% |
| 2022 | $74.2 | $14.8 | -80% |
| 2023 | $14.8 | $13.7 | -7.3% |
| 2024 | $13.7 | $9.84 | -28% |
| 2025 | $9.84 | $12.8 | +30% |
| 2026 YTD | $12.8 | $6.23 | -51% |
NXTC has finished lower in five of the last six years. It's down 51% so far in 2026.